Ad-hoc | 25 June 2002 07:53

Evotec OAI AG english

Evotec OAI Announces Key Management Appointments Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– Evotec OAI AG today announced a number of key management appointments designed to enhance its offering of integrated discovery services and programmes and to prepare the Company for the next phase of its growth. Dr John Kemp, 49, will join Evotec OAI as Chief Executive Officer of Evotec Neurosciences GmbH (ENS), effective July 1, 2002. He will be responsible for Discovery Programmes in the field of the Central Nervous System (CNS). Dr Kemp has 18 years’ research experience in the area of CNS diseases. He joined Hoffmann-La Roche in 1994, where most recently he was Vice President and Head of Preclinical CNS Research. As a consequence of increasing demand for integrated “Target-to-IND-Services” covering all biology and chemistry aspects of drug discovery, Evotec OAI will create a new position, President of Discovery Services, its core business. This organisational change is designed to emphasise the seamless integration of Evotec OAI’s multidisciplinary centres of excellence in Hamburg and Abingdon. The recruitment process for this post is now underway, and in the interim the role will be filled by Chief Executive Officer Joern Aldag. To reflect the Group’s strategy of building significant partnerships with pharmaceutical and biotech companies, Sean Marett, 37, Commercial Director, is promoted to Chief Business Officer and Member of the Management Board, effective July 1, 2002. Sean Marett has contributed significantly to the Company’s success by establishing a powerful marketing and sales organisation and signing many partnership contracts. Before joining Evotec OAI, he was Director of New Product Development, US Operating Division at GlaxoSmithKline. Evotec OAI regrets to announce the departure of Dr Mario Polywka, Chief Operating Officer, who is leaving to take up another senior role in the industry after 11 years at Evotec OAI and Oxford Asymmetry International (OAI). He will leave the Company at the end of August 2002. Dr Polywka has played a major part in the growth and development of the OAI chemistry business, and in the merger and subsequent integration of Evotec Biosystems and OAI in 2000. He leaves behind a well-organised and effective operation. end of ad-hoc-announcement (c)DGAP 25.06.2002 ——————————————————————————– WKN: 566480; ISIN: DE0005664809; Index: NEMAX-50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 250753 Jun 02